These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 26684920)

  • 1. Clotrimazole troches induce supratherapeutic blood levels of sirolimus and tacrolimus in an allogeneic hematopoietic cell-transplant recipient resulting in acute kidney injury.
    El-Asmar J; Gonzalez R; Bookout R; Mishra A; Kharfan-Dabaja MA
    Hematol Oncol Stem Cell Ther; 2016 Dec; 9(4):157-161. PubMed ID: 26684920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease.
    Pidala J; Kim J; Alsina M; Ayala E; Betts BC; Fernandez HF; Field T; Jim H; Kharfan-Dabaja MA; Locke FL; Mishra A; Nishihori T; Ochoa-Bayona L; Perez L; Riches M; Anasetti C
    Haematologica; 2015 Jul; 100(7):970-7. PubMed ID: 25840599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible correlation of sirolimus plasma concentration with sinusoidal obstructive syndrome of the liver in patients undergoing myeloablative allogeneic hematopoietic cell transplantation.
    Kiel PJ; Vargo CA; Patel GP; Rosenbeck LL; Srivastava S
    Pharmacotherapy; 2012 May; 32(5):441-5. PubMed ID: 22499411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: A drug-drug interaction study.
    Kieu V; Jhangiani K; Dadwal S; Nakamura R; Pon D
    Transpl Infect Dis; 2019 Feb; 21(1):e13007. PubMed ID: 30295407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically Significant Drug Interaction Between Clotrimazole and Tacrolimus in Pancreas Transplant Recipients and Associated Risk of Allograft Rejection.
    Viesselmann CW; Descourouez JL; Jorgenson MR; Radke NA; Odorico JS
    Pharmacotherapy; 2016 Mar; 36(3):335-41. PubMed ID: 26877191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
    Cutler C; Kim HT; Hochberg E; Ho V; Alyea E; Lee SJ; Fisher DC; Miklos D; Levin J; Sonis S; Soiffer RJ; Antin JH
    Biol Blood Marrow Transplant; 2004 May; 10(5):328-36. PubMed ID: 15111932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De novo postallogeneic hematopoietic stem cell transplant membranous nephropathy.
    Numata A; Morishita Y; Mori M; Saito O; Takemoto F; Ando Y; Muto S; Yumura W; Kusano E
    Exp Clin Transplant; 2013 Feb; 11(1):75-8. PubMed ID: 22809119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
    Cutler C; Li S; Kim HT; Laglenne P; Szeto KC; Hoffmeister L; Harrison MJ; Ho V; Alyea E; Lee SJ; Soiffer R; Sonis S; Antin JH
    Biol Blood Marrow Transplant; 2005 May; 11(5):383-8. PubMed ID: 15846292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders.
    Ringdén O; Remberger M; Dahllöf G; Garming-Legert K; Karlsson H; Svenberg P; Uhlin M; Uzunel M; Mattsson J
    Eur J Haematol; 2011 Dec; 87(6):503-9. PubMed ID: 22974354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of clotrimazole troches on tacrolimus dosing in heart transplant recipients.
    Laub MR; Crow SA; Personett HA; Dierkhising R; Boilson B; Razonable R
    Transpl Infect Dis; 2018 Dec; 20(6):e12979. PubMed ID: 30120865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rifampin-sirolimus-voriconazole interaction in a hematopoietic cell transplant recipient.
    Wasko JA; Westholder JS; Jacobson PA
    J Oncol Pharm Pract; 2017 Jan; 23(1):75-79. PubMed ID: 26763003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
    Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients.
    Vasquez E; Pollak R; Benedetti E
    Clin Transplant; 2001 Apr; 15(2):95-9. PubMed ID: 11264634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.
    Platzbecker U; von Bonin M; Goekkurt E; Radke J; Binder M; Kiani A; Stoehlmacher J; Schetelig J; Thiede C; Ehninger G; Bornhäuser M
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):101-8. PubMed ID: 19135948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aprepitant (Emend) significantly increases sirolimus levels in patients undergoing allogeneic hematopoietic SCT.
    Shayani S; Palmer JM; Stiller T; Chan H; Keuylian S; Parker P; Thomas S; Pullarkat V; Nademanee A; Forman SJ; Nakamura R
    Bone Marrow Transplant; 2012 Feb; 47(2):291-3. PubMed ID: 21383680
    [No Abstract]   [Full Text] [Related]  

  • 18. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.
    Moore J; Nivison-Smith I; Goh K; Ma D; Bradstock K; Szer J; Durrant S; Schwarer A; Bardy P; Herrmann R; Dodds A
    Biol Blood Marrow Transplant; 2007 May; 13(5):601-7. PubMed ID: 17448920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with optimized tacrolimus dosing in hematopoietic stem cell transplantation.
    Butts AR; Brown VT; McBride LD; Bolaños-Meade J; Bryk AW
    J Oncol Pharm Pract; 2016 Apr; 22(2):275-83. PubMed ID: 25802301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus and mirabegron interaction in a hematopoietic cell transplant patient.
    Engle JA; Fair C
    J Oncol Pharm Pract; 2018 Dec; 24(8):627-631. PubMed ID: 28814193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.